TTR
ENSG00000118271
Target class
Secreted protein
Chromosome
18
Approved drugs
4
Clinical candidates (approved and in development)
4
- Approved drugs
- 4
- ClinGen gene-disease validity
- Definitive
- Clinical candidates (approved and in development)
- 4
- Chemical probe available
- No
- Target name
- TTR
- Gene name
- Transthyretin
- Gene symbol
- TTR
- Protein name
- Transthyretin (ATTR) (Prealbumin) (TBPA)
- HsT2651
- CTS
- PALB
- CTS1
- Gene biotype
- Protein coding
- Gene family
- Gla domain containing
- Target class
- Secreted protein
- Target type
- Human gene
- Tissues expressed in
- 18
- Protein localisation evidence grade
- Approved
- Highest tissue expression
- 2,734.31
- Tissue specificity (Gini)
- 0.967
- Tissue specificity (tau)
- 0.998
- KEGG gene identifiers
- hsa:7276
- Protein interaction confidence
- 0.843784
- Protein interaction partners
- 51
- R-HSA-2453902
- R-HSA-3000171
- R-HSA-6798695
- R-HSA-975634
- R-HSA-977225
- R-HSA-9918449
- End position
- 31606585
- Start position
- 31557009
- Chromosome
- 18
- Strand
- Forward
- Secreted. Cytoplasm.
- Golgi apparatus
- Tissue specificity (tau)
- 0.997578
- Expression inequality (Gini)
- 0.966813
Expression in transcripts per million
- Liver
- 2,734.31
- Pancreas
- 202.76
- Brain - Hippocampus
- 43.78
- Brain - Spinal cord (cervical c-1)
- 26.74
- Brain - Substantia nigra
- 16.68
Expression in transcripts per million
- Liver2,734.31
- Pancreas202.76
- Brain - Hippocampus43.78
- Brain - Spinal cord (cervical c-1)26.74
- Brain - Substantia nigra16.68
- Brain - Hypothalamus15.07
- Stomach8.97
- Brain - Amygdala4.28
- Brain - Anterior cingulate cortex (BA24)3.8
- Pituitary3.05
- Brain - Caudate (basal ganglia)2.52
- Testis2.29
- Kidney - Cortex1.37
- Brain - Cerebellum1.28
- Brain - Cerebellar Hemisphere1.18
- Kidney - Medulla1.15
- Colon - Sigmoid1.06
- Small Intestine - Terminal Ileum1.02
- Esophagus - Gastroesophageal Junction0.95
- Colon - Transverse0.94
- Esophagus - Muscularis0.77
- Brain - Nucleus accumbens (basal ganglia)0.76
- Skin - Sun Exposed (Lower leg)0.59
- Cervix - Endocervix0.57
- Bladder0.56
And 29 more, listed on the interactive page.
Biological processes
- GO:0001523
- GO:0005576
- GO:0035578
- GO:0070062
- GO:0005515
- GO:0042802
- GO:0140313
Related records
Trials (95)
- 24 Month Open Label Study of the Tolerability and Efficacy of Inotersen in TTR Amyloid Cardiomyopathy Patients
- A Bioequivalence Study Comparing Two Different Tafamidis Formulations
- A Drug-Drug Interaction Study To Estimate The Effect Of Tafamidis On Rosuvastatin Pharmacokinetics
- A Extension Study to Evaluate Revusiran (ALN-TTRSC) in Patients With Transthyretin (TTR) Cardiac Amyloidosis
- A Multicenter Observational Study to Evaluate the Effectiveness of Patisiran in Patients With Polyneuropathy of ATTRv Amyloidosis With a V122I or T60A Mutation
- A Phase 1, Single- and Multi-Dose, Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Subcutaneously Administered ALN-TTRSC (Revusiran) in Healthy Volunteers
- A Phase 3 Study of ALXN2060 in Japanese Participants With Symptomatic ATTR-CM
- A Safety and Tolerability Study of an Investigational Drug, ALN-TTRSC02, in Healthy Subjects
- A Single Dose Study to Evaluate the Pharmacokinetics of Acoramidis Modified Release Formulations in Healthy Subjects
- A Study Comparing Amounts of 2 Different Forms of Tafamidis (PF-6291826) in the Blood
- A Study Comparing Amounts of Tafamidis (PF-06291826) in the Blood Without Food in Healthy Volunteers
- A Study Comparing Amounts of Tafamidis In The Blood With Or Without Food
- A Study Comparing Amounts of Tafamidis In The Blood Without Food
- A Study Comparing the Amounts of 2 Different Forms of Tafamidis (PF06291826), Both With and Without Food, In the Blood
- A Study Comparing The Amounts of Tafamidis In The Blood With Or Without Food
- A Study Comparing Two Forms of Tafamidis Without Food and the Amount of Tafamidis in the Blood With Food
- A Study of the Safety, Tolerability and Pharmacokinetics of ALN-TTR02 in Japanese Healthy Volunteers
- A Study to Assess the Long-Term Safety and Efficacy of Eplontersen (Formerly Known as ION-682884, IONIS-TTR-LRx and AKCEA-TTR-LRx) in Patients With Hereditary Transthyretin-Mediated Amyloid Polyneuropathy
- A Study to Assess the PK, PD, Safety and Tolerability of Eplontersen in Healthy Chinese Volunteers
- A Study to Assess the Safety and Efficacy Of Tafamidis In Chinese Participants With Transthyretin Amyloid Cardiomyopathy (ATTR-CM)
Drugs (13)
- Acoramidis Transthyretin stabiliser
- Acoramidis hydrochloride Transthyretin stabiliser
- Eplontersen Transthyretin mRNA antisense inhibitor
- Eplontersen sodium Transthyretin mRNA antisense inhibitor
- Inotersen Transthyretin mRNA antisense inhibitor
- Inotersen sodium Transthyretin mRNA antisense inhibitor
- Patisiran Transthyretin mRNA RNAi inhibitor
- Patisiran sodium Transthyretin mRNA RNAi inhibitor
- Revusiran Transthyretin mRNA RNAi inhibitor
- Tafamidis Transthyretin stabiliser
- Tafamidis meglumine Transthyretin stabiliser
- Vutrisiran Transthyretin mRNA rnai inhibitor
- Vutrisiran sodium Transthyretin mRNA rnai inhibitor